Key facts
- Cytonics’s last known valuation is $104.1M.
- It has raised $39.6M across 1 recorded rounds; the latest was Seed Round ($794K) in Jun 2018.
- Notable investors include DePuy Synthes, National Institutes of Arthritis and Musculoskeletal Diseases, National Institutes of Neurological Disorders and Stroke, River VC.
- Cytonics has filed 5 Form Ds with the SEC since 2009, most recently Jun 2019 ($20K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cytonics
Funding rounds
1 roundsAbout Cytonics
Developer of a diagnostic therapeutics drug designed to improve the treatment of painful osteoarthritis, back, and joint pain. The company's drug offers a Fibronectin-Aggrecan Complex Test for molecular discography and a multi-analyte assay for diagnosing the source of pain in the spine and joints for identification of a naturally occurring blood protein to protect cartilage from degradation, enabling doctors to treat their patients suffering from the musculoskeletal disease.
- Sector
- Healthcare
- HQ
- Jupiter, FL, United States
- Founded
- 2006
- Employees
- 6
- Website
- cytonics.com/
- Ownership
- Privately Held (backing)
Cytonics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytonics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytonics in its N-PORT filings yet. We sweep new filings monthly.